Page 1059 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

6 References

150. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate anti- 166. Riikonen P. Imipenem compared with ceftazidime plus vanco-
microbial therapy results in a fivefold reduction of survival in mycin as initial therapy for fever in neutropenic children with
human septic shock. Chest. November 2009;136(5):1237-1248. cancer. Pediatr Infect Dis J. 1991;10(12):918-923.
151. Schimpff SC, Satterlee W, Young VM, Serpick A. Empiric therapy 167. Norrby SR, Vandercam B, Louie TJ, et al. Imipenem/cilastatin
with carbenicillin and gentamicin for febrile patients with cancer versus amikacin plus piperacillin in the treatment of infections
and granulocytopenia. New Engl J Med. 1971;284:1061-1065. in neutropenic patients: a prospective randomized multiclinic
152. Walsh TR, Toleman MA. The emergence of pan-resistant Gram- study. Scand J Infect Dis. 1987;52(suppl):65.
negative pathogens merits a rapid global political response. 168. Deaney NB, Tate H. A meta-analysis of clinical studies of
J Antimicrob Chemother. January 2012;67(1):1-3. imipenem-cilastatin for empirically treating febrile neutropenic
153. Bush K. Improving known classes of antibiotics: an optimis- patients. J Antimicrob Chemother. 1996;37(5):975-986.
tic approach for the future. Curr Opin Pharmacol. October 169. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy
2012;12(5):527-534. for empiric treatment of febrile neutropenic patients: a meta-
154. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins analysis. J Infect Dis. 1991;164(5):907-916.
for the management of multidrug-resistant gram-negative bac- 170. Winston DJ, Lazarus HM, Beveridge RA, et al. Randomized,
terial infections. Clin Infect Dis. May 1, 2005;40(9):1333-1341. double-blind, multicenter trial comparing clinafloxacin with
155. Satlin MJ, Calfee DP, Chen L, et al. Emergence of carbapenem- imipenem as empirical monotherapy for febrile granulocytope-
resistant Enterobacteriaceae as causes of bloodstream infections nic patients. Clin Infect Dis. 2001;32:381-390.
in patients with hematologic malignancies. Leuk Lymphoma. 171. Bayston KF, Want S, Cohen J. A prospective, random-
April 2013;54(4):799-806. ized comparison of ceftazidime and ciprofloxacin as initial
156. Zinner SH. Changing epidemiology of infections in patients empiric therapy in neutropenic patients with fever. Am J Med.
with neutropenia and cancer: emphasis on gram-positive and 1989;87(5A):269S-273S.
resistant bacteria. Clin Infect Dis. 1999;29(3):490-494. 172. Glauser MP, Brennscheidt U, Cornely O, et al. Clinafloxacin
157. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious monotherapy (CI-960) versus ceftazidime plus amikacin for
Diseases Society of America/American Thoracic Society con- empirical treatment of febrile neutropenic cancer patients. Clin
sensus guidelines on the management of community-acquired Microbiol Infect. 2002;8(1):14-25.
pneumonia in adults. Clin Infect Dis. March 1, 2007;44(suppl 173. Bohme A, Shah PM, Stille W, Hoelzer D. Piperacillin/tazobac-
2):S27-S72. tam versus cefepime as initial empirical antimicrobial therapy
158. Tamura K. Clinical guidelines for the management of neutrope- in febrile neutropenic patients: a prospective randomized pilot
nic patients with unexplained fever in Japan: validation by the study. Eur J Med Res. 1998;3(7):324-330.
Japan Febrile Neutropenia Study Group. Int J Antimicrob Agents. 174. Hess U, Bohme C, Rey K, Senn HJ. Monotherapy with piperacil-
2005;26(suppl 2):S123-S127. lin/tazobactam versus combination therapy with ceftazidime
159. de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen plus amikacin as an empiric therapy for fever in neutropenic
MH, Roila F. Management of febrile neutropenia: ESMO cancer patients. Support Care Cancer. 1998;6(4):402-409.
Clinical Practice Guidelines. Ann Oncol. May 2010;21(suppl 175. Bauduer F, Cousin T, Boulat O, et al. A randomized prospective
5):v252-v256. multicentre trial of cefpirome versus piperacillin-tazobactam in
160. Furno P, Bucaneve G, Del Favero A. Monotherapy or febrile neutropenia. Leuk Lymphoma. 2001;42(3):379-386.
aminoglycoside-containing combinations for empirical antibi- 176. Gorschluter M, Hahn C, Fixson A, et al. Piperacillin-tazobactam
otic treatment of febrile neutropenic patients: a meta-analysis. is more effective than ceftriaxone plus gentamicin in febrile neu-
Lancet Infect Dis. 2002;2(4):231-242. tropenic patients with hematological malignancies: a random-
161. Vardakas KZ, Samonis G, Chrysanthopoulou SA, Bliziotis IA, ized comparison. Support Care Cancer. 2003;11(6):362-370.
Falagas ME. Role of glycopeptides as part of initial empirical 177. Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-
treatment of febrile neutropenic patients: a meta-analysis of ran- label, multicenter comparative study of the efficacy and safety
domised controlled trials. Lancet Infect Dis. 2005;5(7):431-439. of piperacillin-tazobactam and cefepime for the empirical treat-
162. Fainstein V, Bodey GP, Bolivar R, Elting L, McCredie KB, ment of febrile neutropenic episodes in patients with hemato-
Keating MJ. Moxalactam plus ticarcillin or tobramycin for treat- logic malignancies. Clin Infect Dis. 2006;43(4):447-459.
ment of febrile episodes in neutropenic cancer patients. Arch 178. Cometta A, Kern WV, De Bock R, et al. Vancomycin versus
Intern Med. 1984;144(9):1766-1770. placebo for treating persistent fever in patients with neutrope-
163. Jones P, Rolston K, Fainstein V, Elting L, Bodey GP. Aztreonam nic cancer receiving piperacillin-tazobactam monotherapy. Clin
plus vancomycin (plus amikacin) vs. moxalactam plus ticarcil- Infect Dis. 2003;37(3):382-389.
lin for the empiric treatment of febrile episodes in neutropenic 179. Sanz MA, Lopez J, Lahuerta JJ, et al. Cefepime plus amikacin
cancer patients. Rev Infect Dis. 1985;7(suppl 4):S741-S746. versus piperacillin-tazobactam plus amikacin for initial antibi-
164. Flaherty JP, Waitley D, Edlin B, et al. Multicenter, randomized otic therapy in haematology patients with febrile neutropenia:
trial of ciprofloxacin plus azlocillin versus ceftazidime plus ami- results of an open, randomized, multicentre trial. J Antimicrob
kacin for empiric treatment of febrile neutropenic patients. Am Chemother. 2002;50(1):79-88.
J Med. 1989;87(5A):278S-282S. 180. Fleischhack G, Schmidt-Niemann M, Wulff B, et al. Piperacillin,
165. Bliziotis IA, Michalopoulos A, Kasiakou SK, et al. Ciprofloxacin beta-lactam inhibitor plus gentamicin as empirical therapy of a
vs an aminoglycoside in combination with a beta-lactam sequential regimen in febrile neutropenia of pediatric cancer
for the treatment of febrile neutropenia: a meta-analysis of patients. Support Care Cancer. 2001;9(5):372-379.
randomized controlled trials. Mayo Clin Proc. September 181. Shenep JL, Hughes WT, Roberson PK, et al. Vancomycin,
2005;80(9):1146-1156. ticarcillin, and amikacin compared to ticarcillin-clavulanate

Section05-O-ref.indd 6 1/20/2015 4:51:19 PM